Bayer's stocks have taken a significant hit, reaching a
20-year low, driven by a
forecasted fall in 2025 earnings and instability in the European market due to tariffs. The company was ordered to pay an overwhelming
$2B in the latest Roundup case, causing the stock to slump further. Despite quarterly losses and a cautious FY25, Bayer has indicated a potential
growth view commencing from FY26. Regulators have scrutinized the sharp drop in Bayer's share price. Simultaneously, some investors demonstrate confidence in its undervalued shares, signaling a potential buying opportunity. The company seeks
investor approval for a 35% cash call as a protection against litigation. Bayer's near-term outlook faces uncertainty from generic pressures and Crop Science. It also draws attention due to possible
capital raise over legal issues. Bayer reportedly makes efforts to
improve profits in 2026 after a decline this year, with focus on a product offensive in pharmaceuticals. Further, the Roundup lawsuit settlements may require Bayer to issue new stocks. To boost their portfolio, Bayer acquired rights for a cardiovascular drug from CYTK in Japan.
BAYER Stocks News Analytics from Thu, 15 Aug 2024 07:00:00 GMT to Fri, 04 Apr 2025 03:26:11 GMT -
Rating -3
- Innovation 0
- Information 5
- Rumor -4
